Access to COVID-19 Diagnostics
Testing the right people, at the right moment and with the right tool is essential for the Covid-19 pandemic management. Both the Swiss international cooperation and the Swiss pharmaceutical sector have a long-standing experience and interest in supporting R&D, access and manufacturing of diagnostics.. The Foundation for Innovative New Diagnostics (FIND) is leading the global effort (ACT-A Dx Partnership) in the development of affordable COVID-19 diagnostics and local manufacturing capacity for and in LMICs.
Employment & economic development
Health systems strengthening
Tradepolicy & market system
- Other international or foreign NGO North
- Foundation for Innovative New Diagnostics (FIND)
|Objectives||Accelerate universal and equitable access to safe, quality and effective COVID-19 diagnostics|
- Researchers and clinicians in LMICs.
- The global research and development community for COVID-19.
- Manufacturers, regulators and procurement agencies (UNICEF, Global
- Patients and population at high risk for COVID-19.
1. Local manufacturing capacity enhanced to meet regional demand
2. Countries are able to utilize digital solutions as part of their COVID response
- Research and Development: Accelerate development and availability of high performing, affordable rapid diagnostic tools, and create
- Market readiness: Implement market shaping interventions to
- Supply: Identification of supply availability, demand aggregation and
ensure efficient logistics and delivery.
- Country capacity building: Strengthen health systems and build
Results from previous phases: Not applicable. This is a new proposal.
|Directorate/federal office responsible||
International or foreign NGO
Governments, NGOs, private sector
|Coordination with other projects and actors||The ACT-A initiative on therapeutics (Wellcome Trust) and vaccine (Gavi), the WHO Blue Print Project. The Global Fund, WHO|
|Budget||Current phase Swiss budget CHF 26’000’000 Swiss disbursement to date CHF 25’999’550|